ABSTRACT
Background: The global climate change and its consequences force us to remodel our processes and rethink the current model of providing the HD treatments. Waste management have a massive impact on the environment and the economy. Every HD session produces above 1 kg of medical waste, which should be properly stored and destroyed. In particular in the pandemia time we should improve the dialysis unit budget as well as decrease CO2 emission produced during the waste elimination.Materials and Methods: The checked the weight of different dialyzers used regularly in dialysis centers in Poland. The Kern CM 320-IN scale was used for the measurement. The measurement accuracy was 0.1 g. Also the filling volume of each dialyzer has been taken into consideration.Results: The dialyzers were divided into four groups depending on the surface. 1,4m2 in group one, 1.5-1.6 m2 in group two, 1.7-1.8 m2 in group three and finally 2.0-2.2 m2 in group four. FX class dialyzers were lightest in every group. The heaviest ones were Polyflux dialyzers. The difference between the lightest and heaviest dialyzers was about 95 g. The filling volume was lowest in FX dialyzers and the highest in Elisio dialyzers. The difference was 20 mL.Conclusions: The weight of different dialyzers available on the market differs. The decision-makers should take into account this fact as the additional quality feature. In extreme cases the weight difference reaches 95 g. In yearly perspective, the usage of the lighter dialysis set can cause the 17 million kg decrease of medical waste and significant savings.
Subject(s)
Kidneys, Artificial/economics , Medical Waste Disposal/economics , Renal Dialysis/economics , Waste Management/economics , Cost-Benefit Analysis , Environment , Humans , Kidney Failure, Chronic/therapy , Poland , Renal Dialysis/instrumentationSubject(s)
Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/therapy , Kidneys, Artificial/trends , Renal Dialysis/instrumentation , Renal Dialysis/trends , Equipment Design/trends , Health Services Accessibility/economics , Health Services Accessibility/trends , Humans , Kidneys, Artificial/economics , Miniaturization , Renal Dialysis/economics , Wearable Electronic Devices/economics , Wearable Electronic Devices/trendsSubject(s)
Neglected Diseases/prevention & control , Renal Insufficiency, Chronic/prevention & control , Renal Insufficiency, Chronic/therapy , History, 20th Century , History, 21st Century , Humans , Kidneys, Artificial/economics , Kidneys, Artificial/history , Kidneys, Artificial/standards , Kidneys, Artificial/trends , Neglected Diseases/economics , Neglected Diseases/therapy , Renal Insufficiency, Chronic/economicsABSTRACT
Despite almost universal practice of dialyzer reuse from the earliest days of haemodialysis, reusing dialyzer always remains a controversial issue and several ethical concerns have been raised. Some of the important are safety of reuse over single use, informed consent of the patient, conflict of interest on the part of physician or manufacturer, fiscal responsibility and environmental stewardship. Indeed, at the beginning of this century, there was a drastic shift of practice in favour of single use in developed countries due to availability of biocompatible haemodialyzers, at favourable price. Despite this mega shift, dialyzer reuse is still widely practised in low-income countries. Considering cost inflation and limited medical resources in such countries, dialyzer reuse may be justified as a cost-saving strategy for this part of world. However, it poses the same ethical questions to us which were a matter of debate for the western world in the 1980s and 1990s. This review of literature was planned to revisit and highlight these concerns.
Subject(s)
Developing Countries , Equipment Reuse/economics , Ethics, Medical , Kidneys, Artificial/economics , Conflict of Interest , Cost Savings/ethics , Humans , Informed Consent/ethics , Quality of Health CareABSTRACT
The practice of reprocessing dialyzers for reuse, once predominant in the United States, has been steadily declining over the last 20 years. The professed roles of reuse in improving dialyzer membrane biocompatibility and lowering the risk of first-use syndrome have lost relevance with the advent of biocompatible dialyzer membranes and favorable sterilization techniques. The potential for cost-savings from reuse is also called into question by the easy availability of comparatively cheaper dialyzers and rising regulatory demands and operational cost of reprocessing systems. While the environmental concerns from additional dialyzer-related solid waste from rising single-use practice remains pertinent and requires development of safer dialyzer disposable system technologies, there is no meaningful medical rationale for the continued practice of dialyzer reuse in the twenty-first century.
Subject(s)
Equipment Reuse/standards , Kidney Failure, Chronic/therapy , Kidneys, Artificial/statistics & numerical data , Renal Dialysis/instrumentation , Biocompatible Materials/adverse effects , Cost Savings , Equipment Reuse/economics , Equipment Safety , Female , Forecasting , Humans , Kidney Failure, Chronic/diagnosis , Kidneys, Artificial/economics , Male , Membranes, Artificial , Patient Safety , Renal Dialysis/methods , Risk Assessment , United StatesSubject(s)
Immunoglobulin kappa-Chains/isolation & purification , Kidneys, Artificial/economics , Multiple Myeloma/complications , Nephrotic Syndrome/therapy , Renal Dialysis/instrumentation , Acute Kidney Injury/etiology , Acute Kidney Injury/prevention & control , Cost Savings , Female , Humans , Kidneys, Artificial/standards , Middle Aged , Nephrotic Syndrome/complications , Nephrotic Syndrome/etiology , Renal Dialysis/economicsABSTRACT
New directions in dialysis research include cheaper treatments, home based therapies and simpler methods of blood purification. These objectives may be probably obtained with innovations in the field of artificial kidney through the utilization of new disciplines such as miniaturization, microfluidics, nanotechnology. This research may lead to a new era of dialysis in which the new challenges are transportability, wearability and why not the possibility to develop implantable devices. Although we are not there yet, a new series of papers have recently been published disclosing interesting and promising results on the application of wearable ultrafiltration systems (WUF) and wearable artificial kidneys (WAK). Some of them use extracorporeal blood cleansing as a method of blood purification while others use peritoneal dialysis as a treatment modality (ViWAK and AWAK.) A special mention deserves the wearable/portable ultrafiltration system for the therapy of overhydration and congestive heart failure (WAKMAN). This system will allow dehospitalization and treatment of patients with less comorbidity and improved tolerance. On the way to the wearable artificial kidney, new discoveries have been made such as a complete system for hemofiltration in newborns (CARPEDIEM). The neonate in fact is the typical patient who may benefit from miniaturization of the dialysis circuit. This review analyzes the rationale for such endeavour and the challenges to overcome in order to make possible a true ambulatory dialysis treatment. Some initial results with these new devices are presented. We would like to stimulate a collaborative effort to make a quantum leap in technology making the wearable artificial kidney a reality rather than a dream.
Subject(s)
Kidneys, Artificial/trends , Edema/etiology , Edema/prevention & control , Equipment Design , Forecasting , Health Services Accessibility , Heart Failure/complications , Heart Failure/physiopathology , Heart Failure/therapy , Hemofiltration/instrumentation , Humans , Kidney Failure, Chronic/economics , Kidney Failure, Chronic/therapy , Kidneys, Artificial/economics , Kidneys, Artificial/supply & distribution , Miniaturization , Quality of Life , Renal Replacement Therapy/instrumentation , Renal Replacement Therapy/psychology , Renal Replacement Therapy/trends , Ultrafiltration/instrumentationABSTRACT
With the first clinical use of the artificial kidney over 5 decades ago, we entered into a new era of medicine-that of substitutive and replacement therapy. Yet it took nearly another 15 years until chronic treatment was possible and nearly another 15 years until widespread treatment was possible due to government support. The history of development and clinical use of other artificial organ technologies such as the artificial heart and heart valves, the artificial lung, artificial blood, joint replacements, the artificial liver, the artificial pancreas, immunologic, metabolic, and neurologic support, neurocontrol, and tissue substitutes have followed similar long development paths. Despite their relatively long time to be put into clinical use, the contributions of artificial organ technologies to the betterment of mankind have been unquestionably a major success. For example, modern day surgery would not be possible without heart-lung support, and the technologies for heart support have led to the development of various minimally invasive technologies. The powerful impact that artificial organ technologies presently has on our lives is seen through the statistic that in the U.S.A. nearly 1 in 10 persons is living with an implanted medical device. With the aging of our population and the improvements in technologies, these numbers will only increase.
Subject(s)
Artificial Organs/trends , Biomedical Technology , Animals , Artificial Organs/economics , Artificial Organs/standards , Cost-Benefit Analysis , Genomics , Heart, Artificial/economics , Heart, Artificial/standards , Humans , Kidneys, Artificial/economics , Kidneys, Artificial/standards , Liver, Artificial/economics , Liver, Artificial/standards , Robotics , Survival Analysis , Treatment Outcome , United States , User-Computer InterfaceSubject(s)
Insurance, Health, Reimbursement/economics , Kidney Failure, Chronic/economics , Renal Dialysis/economics , Technology, High-Cost/economics , Blood , Blood Volume , Body Temperature , Cost Control , Cost of Illness , Cost-Benefit Analysis , Equipment Design , Hemodiafiltration , Hemofiltration , Humans , Insurance, Health, Reimbursement/statistics & numerical data , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/therapy , Kidneys, Artificial/economics , Monitoring, Physiologic , Quality of Life , Renal Dialysis/instrumentation , Survival Rate , Treatment Outcome , United Kingdom , United StatesABSTRACT
The uremic syndrome is the prototype of a slowly progressive endogenous intoxication, when a detoxifying organ (in this case the kidney) fails. It is characterized by the gradual retention of a host of metabolites, which is in part corrected by dialysis, allowing survival with an acceptable quality of life. This paper reviews the main problems of hemodialysis today, and possible solutions. Adequacy of dialysis is estimated currently from the concentration of urea, which is used as a marker molecule. The problem is that urea is not really toxic by itself. Other markers with known toxicity, such as middle molecules (300-12,000 D) and protein bound compounds should be considered. The question then arises whether the classical dialytic concept based on diffusion should be modified. Adsorptive systems may be strong binders of protein bound solutes. Other concepts that are now arising, and that may add to toxin removal, are slow and daily dialysis. Another question that could be raised is whether it would not be possible to support toxin removal, by administering peroral sorbants. Dialysis patients are prone to vascular disease and die early from cardio-vascular complications. One of the solutions for this problem could be to bring the blood of dialyzed patients into contact with antioxidants (e.g. vitamin C or E). The risk for perdialytic hemodynamic instability is increased in many dialysis patients. The ideal solution would be to develop an "intelligent" dialysis system, whereby blood volume and plasma osmolality are sensed continuously, and ultrafiltration and dialysate sodium concentration are adapted in function of this evolution. An adequate vascular access is indispensable to perform adequate dialysis, but thrombotic/stenotic complications are frequent. This could be prevented by molecular biological modification of vascular grafts, whereby genetic information is entered into the cells, blocking the natural chain of events that otherwise unavoidably leads to neointimal hyperplasia and atherosclerosis. Another old dream is to develop a wearable artificial kidney, whereby patients can move around, and be treated 24 hours per 24 hours, in stead of being treated intermittently at a specific location by the dialysis machine. According to some authors, part of the natural renal function could be replaced by cultured renal tubular cells, which are brought in contact with the blood of the patients. It is concluded that thrilling improvements lie ahead in the future, but the following questions arise: 1) What is the cost of all these improvements? 2) Will it remain possible to reimburse all this? 3) What is going to happen in transplantation, mainly regarding improvements in immunosuppression and the development of xenotransplantation?
Subject(s)
Kidney Failure, Chronic/therapy , Kidneys, Artificial/adverse effects , Kidneys, Artificial/standards , Renal Replacement Therapy/instrumentation , Uremia/therapy , Forecasting , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/psychology , Kidney Transplantation/adverse effects , Kidney Transplantation/standards , Kidney Transplantation/trends , Kidneys, Artificial/economics , Kidneys, Artificial/trends , Quality of Life , Renal Dialysis/adverse effects , Renal Dialysis/psychology , Renal Replacement Therapy/adverse effects , Renal Replacement Therapy/economics , Renal Replacement Therapy/standards , Renal Replacement Therapy/trends , Time Factors , Treatment Outcome , Urea/blood , Uremia/blood , Uremia/mortality , Uremia/psychologyABSTRACT
We evaluated the dialyser reprocessing agent Renalin in a 6-month prospective study of 2,759 dialyses on 59 patients. Dialysers were withdrawn after a maximum of 6 uses, and the average number of uses achieved was 4.5 Dialyser survival varied with the type of dialyser but was unaffected by the dialysate base. In vivo clearances of urea, creatinine and phosphate were not altered by reuse, but there was a small decrease in ultrafiltration characteristics of used dialysers. No clinically significant adverse event was attributed to reuse. Blood pressure was better preserved with used dialysers, and patients experienced significantly fewer intradialytic symptoms. Savings of over +A 25,000 were achieved during the study.
Subject(s)
Disinfectants , Kidneys, Artificial , Renal Dialysis/instrumentation , Sterilization , Acetates , Acetic Acid , Aged , Costs and Cost Analysis , Disposable Equipment/economics , Female , Humans , Hydrogen Peroxide , Kidneys, Artificial/economics , Male , Peracetic Acid , Prospective StudiesSubject(s)
Government Regulation , Health Policy/legislation & jurisprudence , Kidneys, Artificial/standards , Risk Assessment , Centers for Medicare and Medicaid Services, U.S. , Disclosure , Federal Government , Humans , Informed Consent/legislation & jurisprudence , Kidneys, Artificial/economics , Patient Rights , Personal Autonomy , Prospective Payment System , Resource Allocation , Safety , United StatesABSTRACT
To reduce the cost of hemodiafiltration (HDF), a standard hemodialysis machine was modified to permit in-line production of substitution fluid from bicarbonate dialysate. The authors' present data showing that this procedure was made bacteriologically safe; was simple to use, and offered a cheap approach to perform high-flux HDF using a hemodifilter of relatively small membrane surface area.
Subject(s)
Blood , Renal Dialysis , Ultrafiltration , Bicarbonates/therapeutic use , Female , Humans , Kidney Failure, Chronic/therapy , Kidneys, Artificial/economics , Male , Middle Aged , Renal Dialysis/economicsABSTRACT
When Medicare implemented the diagnosis related group (DRG) method of reimbursement for hospitals in 1983, it already had a decade of experience using a prospective payment arrangement for its end stage renal disease (ESRD) program. We reviewed this experience to determine the lessons for Medicare's reimbursement of hospital services. The use of a fixed price for renal dialysis encouraged the introduction of cost-saving techniques. Failure to reduce the price for dialysis in keeping with the cost reductions, however, prevented the government from realizing the full benefits of prospective payment. In addition, there were important changes in medical practice that had independent effects on the program. Similar influences are likely to shape the impact of prospective payment on hospital behavior.
Subject(s)
Diagnosis-Related Groups , Hemodialysis Units, Hospital/economics , Hospital Units/economics , Kidney Failure, Chronic/economics , National Health Programs/economics , Prospective Payment System , Hemodialysis, Home/economics , Humans , Kidney Failure, Chronic/therapy , Kidneys, Artificial/economics , Medicare , Rate Setting and Review , Renal Dialysis/economics , United StatesABSTRACT
The use of the artificial kidney can presently be extended to almost all patients with end-stage renal failure. To reduce the cost of treatment, technological choices have to be made. These are always a compromise between cost and adequacy. The liberty obtained by technical improvements to perform a dialysis "à la carte," depending on patient and doctor wishes, is one of the main characteristics of the present status of hemodialysis.